ESSA Pharma’s Speculative Buy Potential: Masofaniten Promise For Prostate Cancer (EPIX)

Date:


Tubos sanguíneos. Muestras de la enfermedad por PSA. Salud de la próstata. Ciencia de la hematología. Diagnóstico de la enfermedad prostática en el paciente. Matraz de prueba de PSA. Cuerpos rojos alrededor de tubos de ensayo de plástico. Serología

Gri-spb/iStock via Getty Images

ESSA Pharma Inc. (NASDAQ:EPIX) is a clinical-stage pharmaceutical company focused on developing therapies based on N-terminal Domain [NTD] inhibitors, known as Anitens, to disrupt the androgen receptor [AR] and stop prostate cancer growth. EPIX’s leading drug is Masofaniten, which has shown



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

NASA beams Missy Elliott song to Venus

Missy Elliott lyrics blasted off into space as...

U.S. Detected Iranian Plot to Kill Trump Separate From Last Weekend’s Shooting

American intelligence agencies were tracking an Iranian assassination...

Where do both campaigns stand now in the US presidential election? | US Election 2024

Trump nominated by Republicans two days after assassination...